Cargando…
THE ASPREE STUDY: DEMENTIA DUE TO ALZHEIMER’S DISEASE OUTCOMES
In the ASPREE clinical trial, aspirin 100mg daily in health older adults did not delay onset of dementia, a pre-specified secondary outcome over a period of 5 years. We examine whether low-dose aspirin versus placebo is related to incident dementia due to Alzheimer’s disease. Older community-dwellin...
Autor principal: | Shah, Raj C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841487/ http://dx.doi.org/10.1093/geroni/igz038.2359 |
Ejemplares similares
-
ASPREE SUB-STUDIES
por: Woods, Robyn L, et al.
Publicado: (2019) -
POTENTIAL IMPLICATIONS OF ASPREE ON ASPIRIN PRIMARY PREVENTION GUIDELINES
por: Murray, Anne M
Publicado: (2019) -
RATIONALE FOR ASPREE DISABILITY-FREE SURVIVAL PRIMARY OUTCOME AND OVERVIEW OF PRIMARY OUTCOME RESULTS
por: McNeil, John
Publicado: (2019) -
THE ASPREE STUDY: DISABILITY-FREE SURVIVAL, UPDATED RESULTS, SUB-STUDIES, AND IMPLICATIONS FOR ASPIRIN USE
por: Murray, Anne M, et al.
Publicado: (2019) -
EFFECT OF INITIATING ASPIRIN ON CANCER EVENTS IN THE HEALTHY ELDERLY
por: Chan, Andrew T, et al.
Publicado: (2019)